A clinical trial, the results of which were published in 1995, reported that low-dose interleukin-2 (IL-2) and melatonin prolonged the one-year survival and improved the quality of life in patients with metastatic colorectal cancer (CRC), who progressed despite initial response to 5-FU [89]. This evidence concerns the gene IL2 and metastatic colorectal cancer.